Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction

Clinical Ophthalmology

Volumn 8, Issue , 2014, Pages 831-836

  Oleñik, Andrea ^a   Mahillo Fernández, Ignacio ^a   Alejandre Alba, Nicolás ^a   Fernández Sanz, Guillermo ^a   Alarcón Pérez, María ^a   Luxan, Sol ^a   Quintana, Silvia ^a   Martínez de Carneros Llorente, Alfonso ^a   García Sandoval, Blanca ^a   Jiménez Alfaro, Ignacio ^a  

^a Department of Ophthalmology Fundación Jiménez Díaz ^*  (Spain)

Author keywords

Antioxidants; Brudysec ; Nutraceuticals; Polyunsaturated fatty acids

Indexed keywords

BRUDYSEC; OMEGA 3 FATTY ACID; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMOTIONAL DISORDER; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEIBOMIAN GLAND DYSFUNCTION; MENTAL COMPONENT SUMMARY SCORE; MENTAL HEALTH; PAIN; PHYSICAL COMPONENT SUMMARY SCORE; PHYSICAL DISABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL INTERACTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84899720263     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S62470     Document Type: Article

References (31)

1. Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011; 52: 1922-1929.
2. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf. 2004; 2: 149-165.
3. Green-Church KB, Butovich I, Willcox M, et al. The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. Invest Ophthalmol Vis Sci. 2011; 52: 1979-1993.
4. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of meibomian gland dysfunction. Optom Vis Sci. 1990; 67: 710-712.
5. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011; 52: 1994-2005.
6. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The International Workshop on Meibomian Gland Dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011; 52: 1930-1937.
7. Geerling G, Tauber J, Baudouin C, et al. The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011; 52: 2050-2064.
8. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013; 7: 1797-1803.
9. Miljanović B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr. 2005; 82: 887-893.
10. Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye. 2008; 31: 141-146.
11. Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea. 2007; 26: 260-264.
12. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008; 106: 336-356.
13. Kangari H, Eftekhari MH, Sardani S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology. 2013; 120: 2191-2196.
14. Ong NH, Purcell TL, Roch-Levecq AC, et al. Epithelial healing and visual outcomes of patients using omega-3 oral nutritional supplements before and after photorefractive keratectomy: a pilot study. Cornea. 2013; 32: 761-765.
15. Pinazo-Durán MD, Galbis-Estrada C, Pons-Vázquez S, Cantú-Dibildox J, Marco-Ramírez C, Benítez-del-Castillo J. Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. Clin Interv Aging. 2013; 8: 139-148.
16. Galbis-Estrada C, Pinazo-Durán MD, Cantú-Dibildox J, Marco-Ramírez C, Díaz-Llopis M, Benítez-del-Castillo J. Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Clin Interv Aging. 2013; 8: 711-719.
17. Ribelles-Villalba A, Galbis Estrada C, Pinazo Duran MD, Parras Cortes MA. Ojos eco: alternativas terapéuticas frente a los lubricantes oculares a propósito de una prueba piloto [Eco Eyes: therapeutic alternatives to the oculars lubricants: a pilot trial]. Medicina del Trabajo. 2013; 22: 120-129. Spanish.
18. Oleñik A. Effectiveness and tolerability of dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants in the treatment of dry eye symptoms: results of a prospective study. Clin Ophthalmol. 2014; 8: 169-176.
19. Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, Mahillo-Fernández I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging. 2013; 8: 1133-1138.
20. Li M, Gong L, Chapin WJ, Zhu M. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci. 2012; 53: 5722-5727.
21. Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep. 2013; 1: 51-57.
22. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31: 247-263.
23. Tomlinson A, Bron AJ, Korb DR, et al. The International Workshop on Meibomian Gland Dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011; 52: 2006-2049.
24. Alonso J, Prieto L, Antó JM. La versión Española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resulta dos clínicos [The Spanish version of the SF-36 Health Survey (SF-36 Health): An instrument for measuring clinical results]. Med Clin (Barc). 1995; 104: 771-776. Spanish.
25. Vilagut G, Ferrer M, Rajmil L, et al. El cuestionario de salud SF-36 Español: una década de experiencia y nuevos desarrollos [The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments]. Gac Sanit. 2005; 19: 135-150. Spanish.
26. Grubbs JR Jr, Tolleson-Rinehart S, Huynh K, Davis RM. A review of quality of life measures in dry eye questionnaires. Cornea. 2014; 33: 215-218.
27. Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the Beaver Dam Offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014; 157: 799-806.
28. Le Q, Zhou X, Ge L, Wu L, Hong J, Xu J. Impact of dry eye syndrome on vision-related quality of life in a non-clinic-based general population. BMC Ophthalmol. 2012; 12: 22.
29. García-Catalán MR, Jerez-Olivera E, Benítez-Del-Castillo-Sánchez JM. Ojo seco y calidad de vida [Dry eye and quality of life]. Arch Soc Esp Oftalmol. 2009; 84: 451-458. Spanish.
30. Le Q, Ge L, Li M, et al. Comparison on the vision-related quality of life between outpatients and general population with dry eye syndrome. Acta Ophthalmol. 2014; 92: e124-e132.
31. [No authors listed]. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5: 75-92.